Presented in part at the 8th International Conference on Head and Neck Cancer, Toronto, Ontario, Canada, July 21-25, 2012.
The impact of radiographic retropharyngeal adenopathy in oropharyngeal cancer
Article first published online: 3 JUN 2013
Copyright © 2013 American Cancer Society
Volume 119, Issue 17, pages 3162–3169, 1 September 2013
How to Cite
Gunn, G. B., Debnam, J. M., Fuller, C. D., Morrison, W. H., Frank, S. J., Beadle, B. M., Sturgis, E. M., Glisson, B. S., Phan, J., Rosenthal, D. I. and Garden, A. S. (2013), The impact of radiographic retropharyngeal adenopathy in oropharyngeal cancer. Cancer, 119: 3162–3169. doi: 10.1002/cncr.28195
The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.
- Issue published online: 20 AUG 2013
- Article first published online: 3 JUN 2013
- Manuscript Accepted: 26 APR 2013
- Manuscript Revised: 24 APR 2013
- Manuscript Received: 4 MAR 2013
- oropharyngeal cancer;
- retropharyngeal lymph nodes;
- radiation therapy;
We performed this study to define the incidence of radiographic retropharyngeal lymph node (RPLN) involvement in oropharyngeal cancer (OPC) and its impact on clinical outcomes, neither of which has been well established to date.
Our departmental database was queried for patients irradiated for OPC between 2001 and 2007. Analyzable patients were those with imaging data available for review to determine radiographic RPLN status. Demographic, clinical, and outcome data were retrieved and analyzed.
The cohort consisted of 981 patients. The median follow-up was 69 months. The base of the tongue (47%) and the tonsil (46%) were the most common primary sites. The majority of patients had stage T1 to T2 primary tumors (64%), and 94% had stage 3 to 4B disease. Intensity-modulated radiation therapy was used in 77% of patients, and systemic therapy was administered in 58% of patients. The incidence of radiographic RPLN involvement was 10% and was highest for the pharyngeal wall (23%) and lowest for the base of the tongue (6%). RPLN adenopathy correlated with several patient and tumor factors. RPLN involvement was associated with poorer 5-year outcomes on univariate analysis (P<.001 for all) for local control (79% vs 92%), nodal control (80% vs 93%), recurrence-free survival (51% vs 81%), distant metastases-free survival (66% vs 89%), and overall survival (52% vs 82%) and maintained significance on multivariate analysis for local control (P = .023), recurrence-free survival (P = .001), distant metastases-free survival (P = .003), and overall survival (P = .001).
In this cohort of nearly 1000 patients with radiographic RPLN adenopathy in OPC, RPLN involvement was observed in 10% of patients and indicates a negative influence on disease recurrence, distant relapse, and survival. In this cohort of nearly 1000 patients investigating radiographic RPLN adenopathy in OPC, RPLN involvement was observed in 10% of patients and portends a negative influence on disease recurrence, distant relapse, and survival. Cancer 2013;119:3162–3169. © 2013 American Cancer Society.